VRDN

Viridian Therapeutics, Inc. [VRDN] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

VRDN Stock Summary

Top 10 Correlated ETFs

VRDN

Top 10 Correlated Stocks

VRDN

In the News

VRDN Financial details

Company Rating
-
Market Cap
997.38M
Income
-237.63M
Revenue
314K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
94
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-4.85
Forward P/E
-
PEG
-1.34
P/S
3591.61
P/B
3.65
P/C
-
P/FCF
-6.87
Quick Ratio
13.47
Current Ratio
13.93
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-5.32
EPS next Y
-
EPS next Q
-
EPS this Y
35.81%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-23.53%
Revenue last 5Y
-41.18%
Revenue Q/Q
-
EPS Q/Q
23.85%
-
-
-
-
SMA20
-21.12%
SMA50
-35.63%
SMA100
-40.46%
Inst Own
-
Inst Trans
-
ROA
-65%
ROE
-63%
ROC
-0.76%
Gross Margin
100%
Oper. Margin
-66870%
Profit Margin
-61462%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
10.925-30.3
52W High
-56.23%
52W Low
+31.3%
RSI
46.75
Rel Volume
0.98
Avg Volume
948.34K
Volume
927.16K
Perf Week
11.37%
Perf Month
-17.63%
Perf Quarter
-43.79%
Perf Half Y
-46.56%
-
-
-
-
Beta
1.098
-
-
Volatility
0.64%, 1.62%
Prev Close
0%
Price
13.13
Change
4.21%

Something similar

Top by Market Cap
AVGO
NVDA
FB2A.DE
TSLA
GOOGL
Top Correlated ETFs
BBC
CNCR
SBIO
GNOM
IDNA
Top Correlated Stocks
IONS
RCKT
BEAM
KYMR
HOWL
Similar Market Cap
VASWANI.NS
MHM.L
NMFC
0FM2.L
1263.HK

Company Profile

Healthcare Biotechnology
  • Volume Average 948.34K
  • Market Capitalization 997.38M
  • Employee 94
  • CEO Mr. Stephen F. Mahoney J.D., MBA
  • Headquarters Waltham,MA,US
  • IPO Date 2014-06-18
  • Website https://www.viridiantherapeutics.com

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.